Gemini Therapeutics announced the initiation of CLARITY, a disease registry and natural history study designed to identify and characterize disease progression in subjects with non-central geographic atrophy secondary to dry AMD, who are carriers of high-risk genetic variants. CLARITY will be used to inform and optimize the design of future interventional trials. CLARITY will genetically screen and consent thousands of subjects, and will enroll hundreds based on genetic criteria. The screening process will assess dozens of genetic loci with coverage across all known high-risk genetic variants associated with dry AMD. Subjects will be separated into one of two studies: CLARITY, a genetic screening and disease registry will evaluate long-term clinical outcomes and disease progression in subjects who are carriers of functionally consequential genetic variants associated with AMD; CLARITY2, a two-year prospective natural history study will evaluate the clinical characteristics and disease progression in subjects who are carriers of high-risk genetic variants in Complement Factor H (CFH).